School of Food Science and Engineering, Hefei University of Technology, Hefei, Anhui 230009, PR China.
School of Biological and Medical Engineering, Hefei University of Technology, Hefei, Anhui 230009, PR China.
Carbohydr Polym. 2018 Sep 15;196:33-46. doi: 10.1016/j.carbpol.2018.05.006. Epub 2018 May 3.
Combination therapy with chemotherapeutics is attracting increasing attention as an important treatment option for hepatocellular carcinoma (HCC) due to its complex pathological characteristics. In this study, as a new therapy strategy, combination treatment of LEP-2a (a non-toxic polysaccharide from Lachnum sp.) with cyclophosphamide (CTX) was investigated. Results showed that combination treatment with LEP-2a and CTX processed a significantly synergistic anti-tumor effect in H22 tumor-bearing mice through Fas/FasL mediated caspase-dependent death pathway and mitochondria apoptosis pathway. Moreover, our study indicated that LEP-2a played a crucial role in enhancement of immune response, inhibition of tumor angiogenesis and down-regulation of survival associated proteins. Notably, side effects induced by CTX were relieved after LEP-2a treatment. These results support the conception that LEP-2a has the potential as an ideal adjuvant agent for a more effective combination therapy with CTX against HCC.
联合化疗作为一种重要的治疗选择,由于其复杂的病理特征,正越来越受到肝细胞癌(HCC)的关注。在这项研究中,作为一种新的治疗策略,研究了莱普-2a(一种来自节毛属真菌的无毒多糖)与环磷酰胺(CTX)联合治疗。结果表明,莱普-2a 与 CTX 的联合治疗通过 Fas/FasL 介导的半胱天冬酶依赖性死亡途径和线粒体凋亡途径,对 H22 荷瘤小鼠产生了显著的协同抗肿瘤作用。此外,我们的研究表明,莱普-2a 通过增强免疫反应、抑制肿瘤血管生成和下调生存相关蛋白,在增强免疫反应、抑制肿瘤血管生成和下调生存相关蛋白方面发挥了关键作用。值得注意的是,莱普-2a 治疗后 CTX 引起的副作用得到缓解。这些结果支持莱普-2a 作为一种理想的辅助剂,与 CTX 联合应用于 HCC 更有效的联合治疗的观点。